Answers are grounded in this paper and cite their sources.
A double-blind, controlled, clinical trial of spironolactone (Aldactone-A), 50 mg. b. d., showed this to be better than a placebo for the short-term treatment of benign prostatic hypertrophy, although the advantage was not maintained over a longer period of time. There was considerable response to the placebo and the importance of comparative trials with objective measurements is discussed.
No takes yet. Share an insight, caveat, or question.
Castro et al. (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: